Aristotle University Of Thessaloniki (AUTH)
Επίδραση της χαμηλής και υψηλής δόσης ροσουβαστατίνης στη λιπώδη διήθηση του ήπατος την 24ωρη αρτηριακή σκληρία και τις αδιποκίνες ορού σε ασθενείς με μη αλκοολική λιπώδη νόσο του ήπατος
Abstract
dc:descriptionIntroduction: Non-alcoholic fatty liver disease (NAFLD) often coexists with obesity, insulin resistance and dyslipidemia. Hormones, like adiponectin and leptin which are produced by adipose tissue, are involved in the pathogenesis of the disease. Today, there is no effective therapeutic method. NAFLD shares common pathogenetic mechanisms with cardiovascular disease. Also, there are encouraging results from several studies suggesting the beneficial effect of statins on elevated transaminases. Therefore we aimed to evaluate the effect of low (5mg) and high (40mg) dose of rosuvastatin on fatty liver disease, 24-hour arterial stiffness (which is a cardiovascular risk predictor) and serum adipokines in patients with NAFLD. Patients and methods: Patients who visited the outpatient clinic of the Second Propedeutic Department of Internal Medicine of Hippokration Hospital of Thessaloniki due to elevated glutamic pyruvic transaminase (SGPT) (less than 3 times the upper limit of normal) and/or fatty liver disease were included in this study. We excluded patients who reported increased alcohol consumption and those who had another liver disease. The steatosis was evaluated via ultrasound. The NAFLD fibrosis score (NFS) and the Fibrosis-4 index (FIB-4) were used for estimating the severity of fibrosis. We determined the 24-hour arterial stiffness through pulse wave velocity (PWV) and augmentation index (AIx), using the Mobil-O-Graph device. The adiponectin and leptin serum levels were processed by sandwich Enzyme-Linked ImmunoSorbent Assay. Results: 43 patients were included in this study. 21 patients randomized to take 5mg of rosuvastatin and 22 patients took 40mg of rosuvastatin. A follow-up was held after 6 months. Finally, in the group of the low dose of rosuvastatin, nobody had severe steatosis (vs 4,7% at baseline) and 85,7% had normal liver or mild steatosis (vs 52.4% at baseline) (p=0.045). 9.5% and 4.7% had advanced fibrosis, estimated by the NFS and the FIB-4, respectively, while, nobody had advanced fibrosis finally (p=0.003 and p=0.006, respectively). As regards the group of the high dose, 9.1% had severe steatosis initially, whereas, at last, nobody had severe steatosis. Also, 91% had finally mild steatosis or normal liver (vs 40.9% six months before, p=0.012). At baseline, 50% had not advanced fibrosis, estimated by the NFS (vs 54.4% after six months, p<0.001). Additionally, the percentage of patients who had advanced fibrosis estimated by the FIB-4 decreased from 13.6% to 4.6% (p<0,001). Although the PWV was not significantly changed from baseline after 6 months of low dose statin treatment, the AIx was significantly decreased (from 27.47.2% to 25.27.3%, p <0.001). In contrast, in the group of the high dose both PWV and AIx were improved (from 8.11.8 m/s to 7.81.9 m/s, p=0.002 and from 27.49.0% to 22.45.0%, p <0.001). In addition, leptin was significantly decreased (from 18,19,0 ng/ml to 14,38,9 ng/ml, p<0,001) and adiponectin was significantly increased (from 5,33,7 μg/ml to 8,64,3 μg/ml, p<0,001). Conclusions: The outcomes suggest a beneficial effect of rosuvastatin on NAFLD. Either low or high dose improves both steatosis and fibrosis. The dose of 40mg exerts a more beneficial effect compared to the low dose. PWV is reduced only with the high dose of statin, whereas both doses decrease AIx, but the reduction seems to be higher with the high dose. Finally, the high dose significantly decreased leptin and increased adiponectin levels.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Boutari, Chrysoula
- Μπουτάρη, Χρυσούλα
Subjects
dc:subject × 14- Μη αλκοολική λιπώδης νόσος του ήπατος
- Ροσουβαστατίνη
- Αρτηριακή σκληρία
- Αδιποκίνες
- Μη αλκοολική στεατοηπατίτιδα
- Nonalcoholic fatty liver disease
- Rosuvastatin
- Arterial stiffness
- Adipokines
- Nonalcoholic steatohepatitis
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40949